Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Andrew Paul Mazar currently holds 105,000 shares of Monopar Therapeutics (MNPR), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Andrew Paul Mazar has been a net neutral trader of MNPR stock. They have purchased $0 and sold $0 worth of shares.
Andrew Paul Mazar's most recent insider trade was on Apr 1, 2026, when they sold 105,000 shares at $0.00 per share.
Andrew Paul Mazar serves as Executive at Monopar Therapeutics (MNPR). They have executed 13 insider transactions totaling $0 over their tenure at the company.
Andrew Paul Mazar holds the position of Executive at Monopar Therapeutics, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 5 years and currently hold a stake valued at $0.
Andrew Paul Mazar has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by Andrew Paul Mazar was on Jun 30, 2021, when they sold $5.5K worth of MNPR shares. This transaction involved 942 shares at $5.89 per share.
Andrew Paul Mazar currently owns 105,000 shares of Monopar Therapeutics (MNPR), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Andrew Paul Mazar's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Andrew Paul Mazar has 13 Form 4 filings on record as an insider at Monopar Therapeutics.
Set alerts for Andrew Paul Mazar and 40,000+ other insiders.